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Abstract 
Through the histone methyltransferase EZH2, the Polycomb complex PRC2 mediates 
H3K27me3 and is associated with transcriptional repression. PRC2 regulates cell-fate 
decisions in model organisms, however, its role in regulating cell differentiation during 
human embryogenesis is unknown. Here, we report the characterization of EZH2-deficient 
human embryonic stem cells (hESC). H3K27me3 was lost upon EZH2 deletion, identifying an 
essential requirement for EZH2 in methylating H3K27 in hESC, in contrast to its non-essential 
role in mouse ESC. Developmental regulators were derepressed in EZH2-deficient hESC, and 
single-cell analysis revealed an unexpected acquisition of lineage-restricted transcriptional 
programmes. EZH2-deficient hESC show strongly reduced self-renewal and proliferation, 
thereby identifying a more severe phenotype compared to mouse ESC. EZH2-deficient hESC 
can initiate differentiation towards developmental lineages, however, they cannot fully 
differentiate into mature specialised tissues. Thus, EZH2 is required for stable ESC self-
renewal, regulation of transcriptional programmes and for late-stage differentiation in this 
model of early human development. 
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Introduction 
Polycomb-group (PcG) proteins are epigenetic repressors of transcriptional programmes and 
maintain cellular identity during development, differentiation and disease (Di Croce and 
Helin, 2013; Pasini and Di Croce, 2016; Pietersen and van Lohuizen, 2008; Schuettengruber 
and Cavalli, 2009; Surface et al., 2010). PcG proteins form two well-characterized and 
biochemically distinct chromatin-modifying complexes that are termed Polycomb Repressive 
Complex 1 and 2 (PRC1 and PRC2). PRC1 catalyzes histone H2A lysine 119 ubiquitination 
through the activity of the E3 ligases RING1A and RING1B (Muller and Verrijzer, 2009; Wang 
et al., 2004). PRC2 is composed of the core proteins EZH2, EED and SUZ12, together with 
RBAP46/48 and several other accessory subunits, and is responsible for catalyzing di- and 
trimethylation on histone H3 lysine 27 (H3K27me2/3) (Cao et al., 2002; Czermin et al., 2002; 
Kuzmichev et al., 2002; Margueron and Reinberg, 2011; Muller et al., 2002). EZH2 is a SET-
domain containing histone methyltransferase and is the catalytic subunit of PRC2. EED and 
SUZ12 are required for substrate recognition, complex stability and for promoting the 
enzymatic activity of EZH2 (Cao and Zhang, 2004; Nekrasov et al., 2005; Pasini et al., 2004; Tie 
et al., 2007).  
Genome-wide studies in mouse and human embryonic stem cells (ESC) have shown 
that PRC2 and H3K27me3 occupy the promoters of many developmental regulators that are 
important for cell differentiation and lineage specification (Azuara et al., 2006; Bernstein et 
al., 2006; Boyer et al., 2006; Bracken et al., 2006; Lee et al., 2006; Mikkelsen et al., 2007; Pan et 
al., 2007; Zhao et al., 2007). This distribution of chromatin marks led to the concept that PRC2 
may contribute to the maintenance of pluripotency by keeping developmental regulators 
transcriptionally repressed, whilst enabling the genes to be rapidly activated upon suitable 
differentiation cues and stimuli. Despite a central position within the regulatory framework, 
however, PRC2 is dispensable for the maintenance of undifferentiated mouse ESC, as the 
deletion of PRC2 components, including Ezh2, has little effect on their morphology, self-
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renewal or proliferation, although a subset of PRC2 target genes are modestly derepressed 
(Chamberlain et al., 2008; Leeb et al., 2010; Pasini et al., 2007; Riising et al., 2014; Shen et al., 
2008). H3K27me3 levels are globally reduced in Ezh2-deficient mouse ESC, however, 
developmental regulators retain H3K27me3 at their gene promoters and are transcriptionally 
repressed (Shen et al., 2008). In this context, the Ezh2 homologue, Ezh1, forms a noncanonical 
PRC2 complex that is able to trimethylate H3K27 at target gene promoters and maintains 
transcriptional repression through methylation-dependent and potentially methylation-
independent pathways (Margueron et al., 2008; Shen et al., 2008).  
PRC2-deficiency has a more significant impact on mouse ESC upon their 
differentiation, with defects in the repression of pluripotency networks and in the failure to 
fully activate differentiation transcriptional programmes. This aberrant gene regulation 
results in impaired differentiation and proliferation (Chamberlain et al., 2008; Pasini et al., 
2007; Shen et al., 2008). Further underscoring the critical role of PRC2 in directing 
differentiation programmes, all three PRC2 core components (Ezh2, Eed and Suz12) are 
essential for early mouse development, as loss of function mutant embryos initiate but fail to 
complete gastrulation and die between embryonic days 7 and 9 (Faust et al., 1995; O'Carroll 
et al., 2001; Pasini et al., 2004). The mutant phenotype is associated with mis-expression of 
lineage-specifying genes, decreased cell proliferation and an increased level of apoptosis 
(Pasini et al., 2004). 
The well-conserved binding profiles of PRC2 components and H3K27me3 in human 
ESC (hESC) at the promoters of developmental regulators raises the possibility that PRC2 may 
also have an important role in controlling hESC pluripotency and differentiation (Gifford et al., 
2013; Ku et al., 2008; Pan et al., 2007; Zhao et al., 2007). Moreover, coordinated changes to 
the epigenome, including H3K27me3 localization, occur upon differentiation of hESC and are 
thought to be essential for lineage specification and memory of cellular identity, as they are in 
Drosophila and the mouse (Gifford et al., 2013; Xie et al., 2013). However, no functional 
Collinson et al. 
 5 
studies of PRC2 in hESC regulation and early stage differentiation have been reported to date. 
Human pluripotent cells represent a unique model in which to study human development, 
and provide a platform for producing a source of differentiated cells relevant for basic and 
applied research. In addition, mouse and human ESC are known to represent different 
pluripotent states and may therefore rely on different epigenetic pathways to confer their 
ability to self-renew and differentiate (Nichols and Smith, 2009; Rossant, 2015). 
Understanding the key epigenetic mechanisms that underpin hESC is therefore a priority. 
Here, we report the generation and characterization of EZH2-deficient hESC. Our 
findings demonstrate that EZH2 is required to maintain the transcriptional repression of 
developmental regulators and for cells to undergo late-stage cell differentiation, thereby 
revealing the broad conservation of PRC2 function in this model of early human development. 
We also identify unexpected human-specific differences such as the essential requirement in 
hESC for EZH2 to maintain PRC2 stability and retain promoter-localised H3K27me3, which is 
in contrast to its non-essential role in mouse ESC. In addition, self-renewal and proliferation 
are also perturbed to a greater extent in EZH2-deficient hESC, as compared to Ezh2-deficient 
mouse ESC. Our study therefore provides a comprehensive characterization of PRC2 function 
in hESC, thereby providing a new platform to investigate the role of histone methylation in 
regulating the genome during human development and stem cell differentiation. 
 
Results 
Targeted deletion of EZH2 in hESC 
To investigate the role of EZH2 in human pluripotency and differentiation, we used 
CRISPR/Cas9 to disrupt EZH2 in hESC. A guide RNA (gRNA) designed to target an early exon 
within all known EZH2 isoforms was nucleofected with Cas9 into the H9 hESC line (Figures 1A 
and S1A). Individual colonies were isolated, expanded and analysed by Sanger DNA 
sequencing. The efficiency of disrupting the target sequence within the EZH2 coding region 
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was high, with ~35% clonal lines containing a mutation on one allele (EZH2–/). However, no 
homozygous cell lines were obtained out of 110 screened lines. This result provided a first 
indication that EZH2-deficient hESC may be compromised relative to EZH2-containing cells 
when plated as single cells at clonal density. To overcome this apparent defect, we introduced 
a doxycycline (DOX)-inducible EZH2 transgene using piggyBac transposition into an EZH2–/ 
line and re-targeted the cells with EZH2 gRNA and Cas9 in the presence of DOX. Using this 
strategy we obtained several EZH2 homozygous lines (EZH2–/–; Figures 1A and S1B,C). Once 
the EZH2–/– lines were isolated and established, they could be maintained without DOX-
induced EZH2 expression. Although we did not detect any indication that the DOX-inducible 
plasmid was leaky in the absence of DOX, to rule out the possibility of low level EZH2 
expression, we transiently transfected EZH2–/– ESC with piggyBac transposase and obtained 
stable EZH2–/– lines with all copies of the EZH2 transgene removed (Figures S2A,B).  
RNA expression analysis confirmed that EZH2 transcripts were lower in EZH2–/– ESC 
compared to parental EZH2/ and EZH2–/ lines (Figures 1B and S2C). Moreover, EZH2 
protein was undetectable by Western blot and by immunofluorescent microscropy using two 
different antibodies raised against N- and C-terminal epitopes of EZH2 (Figures 1C,D and 
S2D–F). The disruption of EZH2 was accompanied by the loss of other PRC2 proteins, SUZ12 
and EED, despite the presence of unchanged levels of SUZ12 and EED transcripts in EZH2–/– 
ESC (Figures 1B,D). This finding unexpectedly contrasts with Ezh2-deficient mouse ESC where 
Suz12 and Eed levels are unchanged due to the ability of Ezh1 to form noncanonical PRC2 
(Shen et al., 2008), but is consistent with Suz12-deficient and Eed-deficient mouse ESC in 
which PRC2 components are unstable outside of the complex (Pasini et al., 2007; Pasini et al., 
2004). In hESC, therefore, EZH1 is unable to form noncanonical PRC2 despite being present 
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(Figure S2G). EZH1 transcript and protein levels were largely unchanged upon EZH2 deletion 
(Figure S2G). Immunofluorescent microscopy revealed that the loss of EZH2 led to the 
reduction of H3K27me3 and H3K27me2 to background levels, and to the partial reduction of 
H3K27me1 (Figure 1E). Applying DOX to induce ectopic EZH2 expression in EZH2–/– ESC 
restored EZH2 and led to the stabilization of SUZ12 and EED proteins, and to the re-
establishment of global H3K27 methylation (cells designated herein as EZH2–/– +EZH2; Figures 
1B–E). 
 
Loss of promoter-localised H3K27me3 in EZH2-deficient hESC 
To characterise the molecular phenotype of EZH2-deficient hESC, we profiled genome-wide 
histone methylation by native chromatin immunoprecipitation combined with high-
throughput sequencing (ChIP-Seq). Quantitative trend plots of normalized ChIP-Seq reads 
revealed a complete loss of H3K27me3 at all gene promoters in EZH2–/– ESC (Figure 2A). This 
finding contrasts with the retention of H3K27me3 at the promoters of developmental 
regulators in Ezh2-deficient mouse ESC (Shen et al., 2008). Confirming the result in hESC, 
scatter plot analysis of ~2000 promoters that have high levels of H3K27me3 in EZH2  ESC 
(H3K27me3WT) revealed a loss of H3K27me3 in EZH2–/– ESC (Figure 2B). The majority of 
H3K27me3WT promoters have histone H3 lysine 4 trimethylation (H3K4me3) in hESC (Pan et 
al., 2007; Zhao et al., 2007), and H3K4me3 levels were largely unaffected by EZH2 disruption 
(Figure 2B). ChIP-Seq tracks for two example loci, HOXB and HOXD, illustrate the loss of 
H3K27me3 across the domains in EZH2–/– ESC (Figure 2C). Comparison of H3K27me3 
between EZH2  and EZH2–/– +EZH2 cells revealed highly similar profiles, demonstrating that 
histone patterns are appropriately re-established upon EZH2 restoration (Figures 2A-C). 
Interestingly, there was a modest increase in histone H3 lysine 27 acetylation (H3K27ac) 
levels at H3K27me3WT promoters in EZH2–/– ESC, supporting a potential antagonism between 
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H3K27 acetylation and trimethylation that has also been observed in other contexts (Ferrari 
et al., 2014; Gehani et al., 2010; Jung et al., 2010; Pasini et al., 2010; Schoenfelder et al., 2015) 
(Figure S3A). Lastly, an alternative ChIP-Seq analysis strategy of genome binning confirmed a 
loss of H3K27me3 sequencing reads across the genome of EZH2–/– ESC, further reinforcing the 
key finding that H3K27me3 levels are depleted upon deletion of EZH2 in hESC (Figure S3B). 
Together, these results demonstrate that EZH2 is the main functional H3K27me2/3 
methyltransferase in hESC. 
 
EZH2-deficiency causes transcriptional derepression of key developmental genes 
We next performed RNA sequencing (RNA-Seq) to investigate the impact of loss of EZH2 and 
associated H3K27me3 on gene expression. The assays were carried out on samples that were 
flow-sorted using the hESC cell-surface marker SSEA4 to ensure that we compared between 
equivalent cell populations (Figure S4A). The majority of genes were not altered 
transcriptionally by EZH2 disruption, but 911 genes were significantly upregulated and 282 
genes were significantly downregulated in EZH2–/– ESC compared to EZH2–/– +EZH2 ESC 
(p<0.05; Figures 3A and S4B). Gene ontology (GO) analysis of the upregulated gene set 
identified categories associated with developmental and cellular differentiation, including 
pattern specification, embryonic morphogenesis and tissue formation (Figure 3B). The 
upregulated group was significantly enriched for genes with EZH2 and H3K27me3 occupancy 
in EZH2/ ESC and are thus expected to be sensitive to EZH2 disruption (Figures 3C,D). 
Notably, not all genes with EZH2-bound promoters were mis-regulated, suggesting that 
secondary events may be required for this group of genes to initiate transcriptional change in 
response to the loss of EZH2. In addition, a subset of upregulated genes (enriched for 
signalling and adhesion GO terms) are likely to be regulated indirectly as they are not PRC2 
targets in hESC. No GO categories were significantly enriched in the downregulated gene set, 
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although of note, the top category was associated with the regulation of M-phase and indicate 
the decreased transcription of genes typically expressed in mitosis (Figure 3B). 
We examined transcriptional changes in a set of ~100 classical developmental 
regulators that have strong EZH2 promoter occupancy, including genes within the FOX, GATA, 
LHX, T-box and SOX families (Lee et al., 2006). A clear pattern emerges from this analysis: 
nearly all genes within this class of developmental regulator showed transcriptional 
derepression in the absence of EZH2 (Figures 3E and S4C). Gene derepression did not become 
more prevalent upon continued passaging, and therefore the EZH2–/– ESC retained a similar 
transcriptional profile over time. ChIP-Seq and RNA-Seq tracks for several example genes, 
including SOX17, GATA4, T and TBX3, illustrate the absence of promoter H3K27me3 and an 
associated increased transcript level in EZH2–/– ESC (Figure 3F). We further showed that 
shRNA-mediated depletion of EZH2 causes derepression of developmental regulators in two 
additional human pluripotent stem cell lines (WIBR3 and FiPS; Figure S4D). We conclude that 
the deletion of EZH2 in hESC leads to the loss of H3K27me3 and to the transcriptional 
derepression of genes that encode developmental regulators, thereby positioning EZH2 as a 
key factor in controlling the transcriptome of human cell types during early development. 
 
Single-cell transcriptional analysis reveals gene mis-regulation profiles 
To investigate more precisely the transcriptional mis-regulation and cell-to-cell variability in 
response to EZH2 deficiency, we performed single-cell RNA-Seq on individual SSEA4-positive, 
flow-sorted EZH2–/– and EZH2/ ESC. The results show that a subset of EZH2–/– ESC strongly 
upregulated EZH2-target genes, but individual genes are not robustly derepressed in most 
cells examined (Figure 4A). Unexpectedly, clustering of the data suggested that gene 
derepression occurs predominately within discrete transcriptional programmes, such that 
individual EZH2–/– ESC have upregulated multiple genes associated with a particular cell 
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lineage but rarely show strong signatures derived from several cell lineages (Figure 4B). In 
particular, EZH2–/– ESC show lineage biases towards endoderm and mesoderm, but not to 
ectoderm. This response may be constrained by the hESC culture environment due to the 
activities of FGF and Activin/Nodal signalling within the media, which are known to promote 
endoderm and mesoderm specification and supress ectoderm differentiation (Pauklin and 
Vallier, 2015). Together, these results reveal that the depletion of EZH2 does not cause global 
EZH2-target gene derepression in all ESC, as might be predicted from cell population studies. 
Rather, its loss leads to the mis-regulation of subsets of genes and to the acquisition of 
lineage-restricted transcriptional programmes.  
 
EZH2-disruption causes self-renewal and proliferation defects in hESC 
Undifferentiated EZH2-deficient ESC could be maintained in culture for >50 passages, 
however, their growth and morphology were severely compromised compared to control 
lines. EZH2–/– colonies were highly variable in appearance with an increased prevalence of 
flatter cells that are characteristic of spontaneous differentiation (Figure 5A). To compare 
directly the ability of each hESC line to self-renew, we plated an equal number of SSEA4-
positive flow sorted cells at clonal density and after seven days we counted the number of 
colonies that were positive for the undifferentiated hESC marker alkaline phosphatase (AP). 
We observed a ~40% reduction in colony number in EZH2–/– ESC compared to control ESC 
(Figure 5B).  
Diminished colony formation was due to both compromised self-renewal and impaired 
proliferation. Categorising EZH2–/– ESC colonies based on AP activity patterns revealed a 
~50% reduction in the proportion of undifferentiated colonies in EZH2–/– ESC compared to 
control ESC, and an associated increase in the proportion of colonies with a mixed or fully 
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differentiated phenotype (Figure 5C). This was accompanied by a decrease in the proportion 
of EZH2–/– ESC colonies that are entirely OCT4-positive, with an associated increase in the 
proportion of colonies that are positive for SOX17, a marker of early differentiated cells 
(Figure 5D). The proportion of undifferentiated and differentiated cells within the EZH2–/– 
ESC cultures was unchanged over passage, and was re-established after plating of purified 
undifferentiated EZH2–/– ESC, further highlighting the unstable nature of these cells.  
Cell counts over four passages revealed a ~50% reduction in cell number in EZH2–/– 
ESC, revealing that proliferation is significantly reduced in the absence of EZH2 (Figure 5E). 
The mitotic index, as determined by the proportion of histone H3 serine 10 phosphorylation 
(H3S10ph) positive cells, was significantly lower in EZH2–/– ESC compared to control ESC 
(Figure 5F). The reduction in mitotic cells within EZH2–/– cultures is in agreement with our 
RNA-Seq results, which identify the transcriptional downregulation of genes associated with 
M-phase (Figure 3B). Of further relevance to this defect is that several negative regulators of 
the cell cycle, such as CDKN2A (encoding p16INK4A and p14ARF) and CDKN2B (encoding 
p15INK4B), were transcriptionally derepressed in EZH2-deficient ESC (Figure S5). These 
findings are consistent with previous studies in other cell types that have identified a role for 
EZH2 in controlling the transcription of cell cycle regulators (Bracken et al., 2007; Bracken et 
al., 2003; Pasini et al., 2004; Sauvageau and Sauvageau, 2010; Varambally et al., 2002). 
Together, the results demonstrate that EZH2-deficient hESC are strongly compromised in 
their ability to self-renew and proliferate, thereby identifying a more severe phenotype 
compared to mouse ESC that are deficient for Ezh2 and other PRC2 proteins.  
 
Differentiation defects in EZH2-deficient hESC 
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We next investigated the impact of EZH2 deletion on the ability of hESC to differentiate 
correctly. We injected each hESC line into the kidney capsule of three immunocompromised 
mice to test for teratoma formation. Control hESC lines produced teratomas consisting of 
mature cell types derived from all three germ lineages. By contrast, EZH2–/– ESC failed to 
produce teratomas in two mice and generated a very small mass in one mouse, which 
consisted of a restricted set of cell types, including immature adipocytes and epithelial cells 
(Figures 6A and S6A,B). Although the DOX-inducible EZH2 transgene could partially rescue 
the EZH2–/– phenotype, we noticed that the teratomas formed from the EZH2–/– +EZH2 ESC 
were smaller and displayed different morphology compared to the EZH2+/+ and EZH2–/+ ESC 
teratomas (Figure 6A and S6A,B). The difference is likely to be because the cells were not 
provided with DOX once they were injected in situ, and therefore EZH2 levels would be lost 
gradually over several days. Further investigation of EZH2 function in late-stage cell 
differentiation revealed that very few EZH2–/– ESC survived after five days of retinoic acid-
mediated differentiation in vitro, compared to EZH2+/+ and EZH2–/+ ESC (Figure 6B). 
Restoration of EZH2 with the DOX-inducible transgene partially rescued the defect, although 
we noticed that the transgene was silenced at the later stages of cell differentiation, thereby 
hindering a full rescue. Together, these results lead us to conclude that hESC require EZH2 to 
form late-stage differentiated cell types. 
We next studied the early stages of ESC differentiation. PRC2 loss of function mutant 
embryos initiate but fail to complete gastrulation (Faust et al., 1995; O'Carroll et al., 2001; 
Pasini et al., 2004), however, a detailed examination of PRC2-deficient mouse or human ESC 
differentiation towards early developmental progenitors using defined conditions has not 
been reported. To investigate these developmental events, we initiated directed and separate 
differentiation towards endoderm, mesoderm and ectoderm progenitors, using defined 
Collinson et al. 
 13 
conditions and lineage-specific markers (Supplemental Experimental Procedures). We 
observed that cell number declined sharply during endoderm and mesoderm differentiation 
of EZH2–/– ESC, such that very few cells remained by the end of their differentiation protocols 
(Figures 6C,D). In contrast, cell number was maintained in EZH2/ ESC during differentiation. 
We examined the cells at a mid-stage timepoint as this allowed us to obtain sufficient cells for 
analysis. Quantitative analysis of lineage-specific, cell-surface markers using flow cytometry 
showed that EZH2–/– ESC were capable of differentiating into early stage endoderm (defined 
as KIT/CXCR4) (Nostro et al., 2011) and mesoderm (defined as PDGFR/KDR) (Kattman 
et al., 2011) and, surprisingly, formed cell populations at these time points that were more 
uniform in marker expression than achieved upon differentiation of EZH2/ ESC (Figures 
6C,D). To ascertain whether a pre-existing subset of endoderm progenitors were responsible 
for generating endoderm cells in EZH2–/– cultures, we used flow cytometry to separate 
KIT/CXCR4 (endoderm primed) and KIT–/CXCR4– (not endoderm primed) EZH2–/– 
populations and subjected the cells to endoderm differentiation. Flow cytometry analysis 
showed that KIT–/CXCR4– were highly efficient in generating endoderm, thereby 
demonstrating the ability of EZH2-deficient ESC to respond to appropriate differentiation cues 
and initiate early stage differentiation (Figure S6C).  
Upon cell differentiation, pluripotency factors POU5F1, NANOG and SOX2 were 
downregulated to a similar extent in EZH2–/– ESC compared to EZH2/ ESC (Figures 6E,F). 
This finding is in contrast to PRC2-deficient mouse ESC, which exhibit a defect in silencing 
pluripotency networks during cell differentiation (Pasini et al., 2007; Shen et al., 2008). 
Consistent with our RNA-Seq data, genes associated with endoderm and mesoderm 
differentiation were detected at higher levels at day 0 in EZH2–/– ESC compared to EZH2/ 
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ESC, and the transcript level of these genes increased further during differentiation, 
confirming their ability to undergo early stage differentiation (Figures 6E,F). Ectopic 
expression of lineage-restricted genes occurred during EZH2–/– ESC differentiation, 
suggesting a failure to repress alternate transcriptional programmes (Figures 6E,F).  
EZH2-deficient cells were also able to generate early ectoderm cells (defined as 
CD56+/CD326–) (Gifford et al., 2013), however, cell number during differentiation and the 
efficiency of differentiation were significantly reduced compared to EZH2/ ESC (Figure 6G). 
Mis-regulation of lineage-restricted genes was observed upon ectoderm differentiation, 
thereby identifying a requirement for EZH2 in regulating appropriate gene expression in the 
early stages of ectoderm specification (Figure 6H).  
Taken together, these results demonstrate that EZH2 is not required for the initial 
phase of hESC differentiation, but is required for the robust generation of mature cell types 
that are produced in the later stages of differentiation in vitro or in teratoma assays. 
 
Discussion 
PcG-proteins are essential regulators of cell fate decisions and transcriptional programmes 
during the development of several species, including Drosophila and the mouse. Here, we 
show that this important function is also required in humans during the establishment of 
early developmental cell types that arise upon ESC differentiation (Figure 7). Furthermore, 
loss of EZH2 function in undifferentiated hESC led to the transcriptional derepression of ~900 
genes including many important developmental regulators, thereby positioning EZH2 as a key 
factor in controlling the transcriptome of human cell types during early development. 
Interestingly, not all PRC2-target genes were mis-regulated, suggesting that redundant modes 
of transcriptional repression are in place, or that additional cues (such as transcription factor 
binding) are required to fully activate those genes. In addition to developmental factors, we 
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also detected an increased expression of cell-cycle regulators in the absence of EZH2, 
including CDKN2A (encoding p16INK4A and p14ARF) and CDKN2B (encoding p15INK4B). 
Given the close association between cell-cycle control and cell differentiation in hESC (Pauklin 
and Vallier, 2013; Gonzales et al., 2015; Pauklin et al., 2016), it is likely that both processes 
contribute to the phenotype of EZH2-deficient cells. For example, an upregulation of 
p16INK4A would inhibit CDK4/6, which, in turn, would lead to an increase in Activin/Nodal 
activity (Pauklin and Vallier, 2013). This signalling change would promote the transcriptional 
programmes of endoderm and mesoderm lineages, and suppress ectoderm differentiation. 
We speculate, therefore, that the increased expression of endoderm and mesoderm genes in 
EZH2-deficient hESC is caused jointly by the removal of repressive H3K27me3 marks, by 
altered signalling activities that are mediated by cell-cycle machinery, and by the cell culture 
environment. Notably, our transcriptional results are consistent with a recent study that 
reported derepression of a subset of PRC2-target genes in Ezh2-deficient mouse epiblast 
tissue, thereby underscoring the relevance of our observations to pluripotent cells in vivo 
(Zylicz et al., 2015). Importantly, our analysis of individual cells further revealed that 
misregulation of genes tended to occur in a coordinated manner within lineage-restricted 
transcriptional programmes, rather than a haphazard derepression of all PRC2-target genes 
as might be predicted from global cell population analysis. These results suggest the presence 
of feedback mechanisms that are able to promote or repress alternative cell fates during the 
early phases of differentiation. An exciting set of future studies will be to model and 
investigate the mechanisms responsible for this feedback. Our findings also raise broader 
questions about how cells are committed to a particular lineage during differentiation. 
Purifying live hESC populations that are in different transcriptional states and challenging the 
cells to functional assays should begin to unravel the complexities of cell fate commitment 
during human development. 
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Despite extensive conservation in their functions, differences exist between mouse and 
human ESC that lack EZH2; self-renewal, morphology and proliferation are seemingly 
perturbed to a greater extent in human EZH2–/– ESC compared to mouse Ezh2–/– ESC (Shen et 
al., 2008). One potential explanation is that differences in PRC2 protein stability or function 
could contribute to the distinct mouse and human ESC phenotypes. For example, Eed and 
Suz12 levels are unaffected by the loss of Ezh2 in mouse ESC, potentially due to a partial 
compensation by Ezh1 (Shen et al., 2008). In contrast, we show here that depletion of EZH2 in 
hESC results in loss of EED and SUZ12, despite the presence of EZH1. Interestingly, Ezh1 
cannot compensate for the absence of Ezh2 during mouse ESC differentiation or embryo 
gastrulation (O'Carroll et al., 2001; Shen et al., 2008). We speculate there is a context-
dependent role for Ezh1 and that the compensatory function diminishes as cells enter the 
post-implantation phase of development, which could partially explain the apparent inability 
of EZH1 to fulfil a compensatory role in EZH2-deficient hESC. In addition, Ezh1 is able to 
repress gene transcription through methylation-independent mechanisms in somatic cells, 
potentially via chromatin compaction (Margueron et al., 2008). It will therefore be interesting 
in future studies to more precisely define the functional interplay between EZH1 and EZH2 in 
early human developmental cell types.  
A second potential explanation for the distinct phenotypes is that mouse and human 
ESC are known to represent different pluripotent states, with hESC considered to be primed 
for differentiation (Nichols and Smith, 2009; Rossant, 2015). The EZH2-deficient phenotype 
may therefore manifest differently depending on cell state; a concept recently proposed for 
DNMT1-depleted ESC (Liao et al., 2015). It will be important in future studies to test this 
hypothesis by investigating the role of PRC2 in human ‘naïve’ pluripotent cells, which are 
reported to be more similar to mouse ESC (Manor et al., 2015). Furthermore, it is interesting 
to consider that PRC2 may contribute to the balance required for primed-state pluripotency 
by enabling low-level expression of lineage-specifying developmental regulators whilst 
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constraining their levels so that they do not overwhelm the maintenance of the 
undifferentiated state. Given that the ectopic expression of several EZH2 target genes, such as 
SOX17 and GATA6, can induce the differentiation of hESC (Seguin et al., 2008; Wamaitha et al., 
2015), it is plausible that derepression of these and other developmental regulators in the 
absence of EZH2 results in a shift towards an increased level of spontaneous differentiation 
that is observed in EZH2-deficient hESC. Thus, our analysis of PcG function in hESC should 
lead to a better understanding of the processes that regulate lineage priming and cell fate 
commitment, and inform similar events that occur in other species and cell types. 
 Genome-wide mapping has revealed that dynamic changes in epigenetic marks, 
including H3K27me3 localization, occur upon hESC differentiation (Gifford et al., 2013; Xie et 
al., 2013). A prevailing model proposes that this epigenetic reconfiguration is required to 
coordinate transcriptional programmes and provide a memory of cell identity. We have now 
tested this model and we show that EZH2 is not required for the initial phase of hESC 
differentiation as ectoderm, mesoderm and endoderm germ lineages can form in the absence 
of EZH2, however, the mutant cells mis-express lineage-specific genes, are unstable and are 
gradually lost over the differentiation timecourse. Interestingly, and in contrast to PRC2-
deficient mouse ESC (Pasini et al., 2007; Shen et al., 2008), pluripotency genes were 
downregulated appropriately upon differentiation of EZH2-deficient hESC, suggesting that 
these genes are silenced by PRC2-independent pathways. The observed differentiation defects 
and reduction in cell survival are therefore unlikely to be caused by aberrant expression of 
pluripotency factors, but rather by mis-expression of lineage-specifying genes and cell-cycle 
regulators. Finally, although the EZH2-deficient hESC were unable to form mature cell types, 
the rescue of early differentiation defects by conditionally restoring EZH2 levels should enable 
the role of PRC2 to be investigated during late-stage in vitro differentiation. As the EZH2–/– 
+EZH2 cells could not fully recapitulate the parental wild-type cells in the teratoma and the RA-
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differentiation experiments, alternative conditional systems might be better suited for the 
investigation of EZH2 in late-stage cell differentiation. Interestingly, the results from our 
teratoma experiments suggest that once the EZH2–/– ESC have overcome the initial early-stage 
differentiation barrier (enabled by residual EZH2), they are able to specialize along certain 
tissue lineages. The differences in morphology and tissue composition of the teratomas are 
presumably, to some extent, a reflection of what differentiation pathways are accessible to 
EZH2-deficient cells. Future studies using alternative conditional strategies and more precise 
differentiation systems should lead to a better understanding of epigenetic modifiers in the 
generation of specialized cell types. Artificially controlling EZH2 levels may also have useful 
practical applications in producing desired cell types, as has been demonstrated recently to 
boost production of beta cell progenitors (Xu et al., 2014).  
Taken together, our study provides a comprehensive examination of EZH2 function in 
hESC pluripotency and differentiation. Of note is that PRC2 mediates the self-renewal and 
differentiation of adult stem cells and cancer stem cells (Sauvageau and Sauvageau, 2010). 
Our findings therefore not only reveal the role of epigenetic modifiers and associated histone 
marks in regulating the genome during early human development, but also establish general 
principles that can be applicable to stem cells involved in homeostasis and disease. 
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Experimental Procedures 
 
Cell culture 
HESC (H9/WA09, obtained from WiCell; WIBR3, kindly provided by Rudolph Jaenisch; FiPS, 
kindly provided by Austin Smith) were cultured at 37°C in 5% CO2 in air on CF1 irradiated 
mouse embryonic fibroblasts (MEF) in Advanced DMEM containing 20% Knockout Serum 
Replacement supplemented with 2mM L-Glutamine, 0.1mM -mercaptoethanol, 1x 
Penicillin/Streptomycin, 1x Non-Essential Amino Acids (all from Thermo Fisher Scientific) 
and 4ng/ml FGF2 (WT–MRC Cambridge Stem Cell Institute). Where indicated, DOX was added 
at 1g/ml. For feeder-free culture, ESC were transferred onto Vitronectin matrix in TeSR-E8 
media (StemCell Technologies). Authentication of the hESC was achieved by confirmation of 
expression of pluripotency gene and protein markers. Cells were routinely verified as 
mycoplasma-free using a PCR-based assay. Additional cell culture materials and methods are 
detailed in Supplemental Experimental Procedures.  
 
Targeted deletion of EZH2 
EZH2 gRNA (CCGCTTCTGCTGTGCCCTTATC) was designed using http://crispr.mit.edu (Hsu et 
al., 2013). The gRNA sequence was incorporated into the U6 target gRNA expression vector 
(Mali et al., 2013) and synthesised as a gBlock by Integrated DNA Technologies. The EZH2 
gRNA gBlock was sub-cloned into pCR2.1-TOPO (Thermo Fisher Scientific) and verified by 
sequencing. HESC were dissociated into single cells using Accutase (Thermo Fisher Scientific). 
H9 ESC (2 million) were nucleofected with 5μg pCas9_GFP (Addgene plasmid # 44719) and 
5μg EZH2 gRNA expression vector. After 48h, 10,000 GFP-positive single cells were isolated 
by FACS and seeded onto MEF in a 10cm tissue culture dish in ESC media supplemented with 
10μM Rho Kinase inhibitor (Cell Guidance Systems) for the first 24h. Individual clones were 
picked and expanded in 24 well plates. Mutations were validated by DNA sequencing of TOPO 
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cloned PCR products. As a check for specificity, ten predicted off-target gRNA sites within 
genes were tested and verified to contain unmodified sequences. 
 
Plasmid constructs 
To construct PB-TET-EZH2-ires-mCherry plasmid, the EZH2 coding sequence was amplified 
using primers EZH2_attb_F and EZH2_attb_R and sub-cloned into PB-TET-ires-mCherry 
plasmid. To generate EZH2–/– +EZH2 ESC, EZH2–/+ ESC were lipofected with 1μg PB-TET-EZH2-
ires-mCherry, 1μg pCAG-rtTA-Puro and 2μg pCyL43 (Wang et al., 2008) followed by selection 
with 1μg/ml Puromycin.  
To remove PB-TET-EZH2-ires-mCherry, DOX-induced EZH2–/– +EZH2 ESC were 
nucleofected with 5μg pCMV-hyPBase (Yusa et al., 2011) and 1μg Turbo-GFP (Lonza). After 
48h, 10,000 GFP / mCherry double-positive single cells were isolated by FACS and seeded 
onto MEF in a 10cm tissue culture dish in ESC media supplemented with 10μM Rho Kinase 
inhibitor for the first 24h. Individual clones were picked and expanded in 24-well plates. DNA 
was genotyped using mCherry_Geno and TET-Prom_Geno primers to confirm removal of PB-
TET-EZH2-ires-mCherry. 
 
Statistics 
For Figure 3D, the data are significantly departed from normality (p<0.05; D’Agostino-
Pearson omnibus normality test) and the variance is different between the groups (p<0.05; 
Brown-Forsythe test) therefore a non-parametric test was used. For statistical analysis of data 
within Figures 5 and 6, the scatter of the data lead us to assume that the samples comes from 
a normally distributed population and that the variability between the groups is about the 
same, therefore parametric tests were used. 
 
Data availability 
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Sequencing data have been deposited in Gene Expression Omnibus with accession number 
GSE76626. 
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Figure legends 
 
Figure 1. Targeted deletion of EZH2 in hESC 
(A) Overview of EZH2 structure and targeting strategy. Exons encoding CXC and SET domains 
are indicated. The gRNA sequence is underlined and protospacer adjacent motif highlighted in 
red. DNA sequence of the deletions in one EZH2–/ ESC line and one EZH2–/– ESC line is shown 
for both alleles. Mutation causes frameshift and premature stop codon. An additional line is 
shown in Figures S1 and S2. 
(B) mRNA expression levels from RNA-Seq data revealing EZH2, EED and SUZ12 transcript 
levels in EZH2/, EZH2–/, EZH2–/– and EZH2–/– +EZH2 ESC. Data show mean ± s.d.; n=3 
biological replicates. 
(C) Immunofluorescent microscopy of colonies from EZH2–/– ESC and control ESC. This 
analysis reveals a strong reduction in EZH2 levels in EZH2–/– ESC. The antibody was raised 
against a C-terminal epitope of EZH2; similar results were obtained using an alternative 
antibody raised against the N-terminal of EZH2 (Figure S2E). OCT4 expression indicates 
undifferentiated cells within a hESC colony. Arrows point to MEF. Scale bars, 100μm. 
(D) EZH2, SUZ12 and the main isoform of EED are undetectable in EZH2–/– ESC by Western 
blot analysis, and are restored upon expression of a DOX-induced EZH2 transgene. -ACTIN is 
the loading control. Mass in kDa. 
(E) H3K27me3 and H3K27me2 levels are reduced to background levels, and H3K27me1 
levels are partially reduced, in EZH2–/– ESC. OCT4 expression in inset indicates 
undifferentiated ESC within the field of view. Arrows point to MEF. Scale bars, 100μm. 
 
Figure 2. EZH2-deficiency in hESC results in loss of H3K27me3 
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(A) Quantitative trend plot of H3K27me3 normalised ChIP-Seq reads over gene body ± 5kb. 
High CpG (HCP), intermediate CpG (ICP) and low CpG (LCP) promoters are shown separately. 
(B) Scatter plot of H3K27me3 (x-axis) and H3K4me3 (y-axis) normalised ChIP-Seq reads in 
EZH2–/– relative to EZH2  (left) and relative to EZH2–/– +EZH2 (centre), and EZH2–/– +EZH2 
versus EZH2  (right). All TSS shown in grey; TSS that are positive for H3K27me3 in EZH2  
ESC highlighted in blue. Disruption of EZH2 leads to a strong reduction in H3K27me3 levels at 
TSS, with little effect on H3K4me3 levels. Expression of a DOX-mediated EZH2 transgene in 
the EZH2-deficient cells causes restoration of H3K27me3 levels to levels equivalent to 
EZH2 . 
(C) ChIP-Seq tracks of HOXB (left) and HOXD (right) loci illustrate the loss of H3K27me3 in 
EZH2–/– ESC compared to control ESC. H3K4me3 is relatively unaffected. All ChIP-Seq data 
represent the average of three biological replicates for each cell line. These results were 
confirmed independently by qPCR analysis of ChIP DNA at several gene promoters (Figure 
S3C). 
 
Figure 3. Genes encoding developmental regulators are transcriptionally derepressed 
in EZH2-deficient hESC 
(A) RNA-Seq heatmap for EZH2–/– ESC and control ESC (three biological replicates per line). 
Shown are all differentially expressed genes between EZH2–/–and EZH2–/– +EZH2 ESC. 
(B) Top GO terms of differentially expressed gene sets. Numbers of genes are shown; example 
genes within each GO category are listed (right). Corrected p-values were calculated using a 
modified Fisher's exact test followed by Bonferroni's multiple comparison test. 
(C) Gene set enrichment analysis of PRC2 targets (n=1299; defined by high EZH2 and 
H3K27me3 promoter-localised ChIP-Seq values in EZH2+/+ ESC) in genes that have been 
ranked according to their fold-change in transcription between EZH2–/– ESC and EZH2–/– +EZH2 
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ESC. The positive enrichment score (ES) reveals that genes selectively derepressed in the 
absence of EZH2 are enriched in PRC2 targets (p<0.001; Kolmogorov-Smirnov statistic). 
(D) Genes within the upregulated category have higher levels of promoter-localised EZH2 
(upper) and H3K27me3 (lower) in EZH2+/+ ESC compared to an expression-matched set of 
genes and to downregulated genes. Data were compared using a Kruskal-Wallis test followed 
by Dunn's multiple comparison test. 
(E) Genes encoding developmental regulators are transcriptionally derepressed in EZH2-
deficient ESC. A subset of direct EZH2 target genes is depicted as family groups. The colour of 
each circle represents the log2 fold change in EZH2–/– ESC relative to EZH2–/– +EZH2 ESC. The 
size of each circle represents the expression value of the gene in EZH2–/– cells. A similar 
pattern of target gene derepression is observed when comparing EZH2–/– ESC with EZH2/ 
ESC (Figure S4C). 
(F) ChIP-Seq and mRNA-Seq tracks of four genes encoding key developmental regulators 
illustrate the association between loss of H3K27me3 and transcriptional upregulation in 
EZH2–/– ESC. 
 
Figure 4. Transcriptional derepression occurs predominantly within discrete lineage-
specific programmes 
(A) Single-cell RNA-Seq expression levels for six example PRC2-target genes in EZH2–/– ESC 
and EZH2/ ESC, where each dot represent the results from a single cell. A pluripotency gene 
(LIN28) and housekeeping gene (HMBS) are shown for comparison. Robust upregulation of 
PRC2-target genes occurs in a subset of EZH2–/– ESC. 
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(B) Heatmap of single-cell RNA-Seq expression for EZH2–/– ESC (right) and EZH2/ ESC (left). 
Each column represents an individual cell. Each row represents an individual gene, grouped 
into three clusters corresponding to endoderm, mesoderm and ectoderm cell lineages. Shown 
are PRC2-target genes from within the hESC Scorecard assay, which is an assay that can 
classify differentiated cell lineages (Bock et al., 2011). Subsets of cells (boxed in purple) tend 
to mis-express many genes from within one lineage, but rarely mis-express multiple genes 
derived from more than one lineage. 
 
Figure 5. EZH2-deficient hESC are compromised in self-renewal and proliferation 
(A) Phase contrast images show representative colonies of EZH2/, EZH2–/– and EZH2–/– 
+EZH2 ESC lines. Note the variable morphology of EZH2-deficient colonies. Scale bars, 100μm. 
(B) EZH2–/– ESC show reduced ESC colony formation when plated as single SSEA4-positive 
cells at low density (6000 cells seeded per well). Data show mean ± s.d.; n=3 biological 
replicates. Data were compared using a one-way ANOVA followed by Bonferroni's multiple 
comparison test (***, p<0.0005). Representative AP staining is shown underneath. 
(C) EZH2–/– ESC have reduced capacity to self-renew when plated at clonal density. ESC 
colonies were categorised as undifferentiated, mixed or differentiated based on AP activity; 
examples shown underneath. Data show mean ± s.d.; n=3 biological replicates. Over 150 
colonies were scored for each cell line.  Data were compared using a one-way ANOVA 
followed by Bonferroni's multiple comparison test (***, p<0.0005; **, p<0.005; *, p<0.05). 
Scale bars, 100μm. 
(D) Immunofluorescent microscopy for OCT4 (undifferentiated marker) and SOX17 (early 
differentiation marker) reveals an increased prevalence for mixed and fully differentiated 
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colonies in EZH2–/– compared to control ESC lines. Representative images are shown 
underneath. Over 100 colonies were scored for each cell line. Scale bars, 100μm. 
(E) Growth curve over 16 days reveals a significant proliferation defect in EZH2–/– ESC 
compared to control ESC. Data show mean ± s.d.; n=3 biological replicates. Data were 
compared between EZH2–/– ESC and each control ESC line using one-way ANOVA followed by 
Bonferroni’s multiple comparison test (*; p<0.05 for each comparison). 
(F) Mitotic index was calculated for each ESC line by dividing the number of H3S10ph-positive 
cells by the total number of cells within a colony. The analysis was restricted to 
undifferentiated colonies (determined by OCT4 expression) of similar size in order to control 
for potential differences in cell state. Over 1000 cells were scored for each cell line. Data show 
mean ± s.d.; n=3 biological replicates. Data were compared using a one-way ANOVA followed 
by Bonferroni's multiple comparison test (***, p<0.0005). Scale bars, 100μm. 
 
Figure 6. EZH2-deficient hESC can initiate differentiation, but are severely impaired in 
generating mature cell types 
(A) EZH2–/– ESC fail to generate teratomas. Mass of teratoma and kidney samples for 
indicated ESC lines, with images shown underneath (scale bar, 5mm). Additional images and 
histology analysis are provided in Figures S6A,B. 
(B) ESC were induced to differentiate with retinoic acid for five days. Cell counts (upper) and 
crystal violet stain (lower) reveal that few EZH2–/– ESC remain after five days compared to 
control ESC. Short bars indicate mean values for the two biological replicates. 
(C) EZH2-deficient ESC can generate early endoderm cells. Upper panel shows cell counts over 
endoderm differentiation timecourse. Lower panel shows flow cytometry analysis of 
endoderm markers KIT/CXCR4 in undifferentiated EZH2/ ESC (black), day 5 endoderm 
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differentiated EZH2+/+ (blue), undifferentiated EZH2–/– ESC (red), and day 5 endoderm 
differentiated EZH2–/– (purple). Inset numbers show percentage positive cells for each cell 
population (mean of three biological replicates, with range). 
(D) EZH2-deficient ESC can generate early mesoderm cells. Upper panel shows cell counts 
over six days of mesoderm differentiation. Lower panel shows flow cytometry analysis of 
mesoderm markers KDR/PDGFRα. 
(E) RT-qPCR analysis of endoderm, mesoderm, ectoderm and pluripotency genes in 
undifferentiated (black) and day 5 endoderm differentiated (blue) EZH2/ ESC, and 
undifferentiated (red) and day 5 endoderm differentiated (purple) EZH2–/– ESC. Note that 
POU5F1 and NANOG are also associated with ESC differentiation (Loh and Lim, 2011), which 
may underlie their elevated expression patterns in EZH2–/– ESC. 
(F) qRT-PCR analysis of undifferentiated and day 2 mesoderm differentiated ESC. 
(G) EZH2-deficient ESC can generate early ectoderm cells, but with significantly reduced 
efficiency compared to EZH2+/+ ESC. Upper panel shows cell counts over 10 days of ectoderm 
differentiation. Lower panel shows flow cytometry analysis of ectoderm marker CD56 and 
undifferentiated ESC marker CD326. Note the significantly decreased efficiency of ectoderm 
differentiation in EZH2–/– ESC compared to EZH2  ESC (p=0.01; unpaired two-sided t-test). 
(H) RT-qPCR analysis of undifferentiated and day 10 ectoderm differentiated ESC. For all 
panels, data show mean ± s.e.m of 3 biological replicates and were compared using an 
unpaired two-sided t-test (*, p<0.05). 
 
Figure 7. Proposed model summarising the role of EZH2 in regulating transcriptional 
programmes and cell differentiation in hESC 
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EZH2+/+, above; and EZH2–/–, below. EZH2-deficiency leads to loss of PRC2, transcriptional 
derepression of developmental regulators and self-renewal defects in hESC. Substantial cell 
loss (red crosses) and gene mis-regulation is observed upon differentiation of EZH2–/– ESC 
(e.g. to endoderm in example shown). 
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